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Abstract
Background Economic evaluation helps policy makers and
healthcare payers make decisions on drug listing, coverage,
and reimbursement. When economic evaluations are con-
ducted before a product launch, the prices of the pharma-
ceuticals have to be forecast.
Objective The aim of this study was to examine the
methods of establishing proxy prices and their accuracies
compared with actual market prices after the product
launch.
Methods We searched the literature for evaluations for
drugs that were licensed in the US between 2010 and 2015.
We reviewed the studies for the forecasting strategies used,
and then estimated the difference between actual 2016
post-launch prices and what the proxy prices would be if
the forecast was carried out in the US in 2016.
Results We identified six such studies, with seven drugs.
Four studies used substitute drugs as proxies for the study
drug, and three used other methods. The range of the values
of actual minus proxy price varied considerably, and no
trend was observed.
Conclusion Forecasting drug prices is as precarious as
forecasting in other areas of the economy. We urge caution
in reviewing and accepting a cost-effectiveness ratio that is
based on forecast prices.
Key Points for Decision Makers
When pre-launch prices are estimated, the price of a
close substitute is the most common variable used to
estimate the prices of study drugs, followed by the
price in a country where the drug is licensed.
Although sensitivity analysis is not widely used, it is
an important component of a forecasting study.
In general, forecasted prices, when used in economic
evaluations, have varied considerably from actual
prices, especially when there is no close substitute on
which to base the forecasted price.
1 Introduction
Economic evaluation helps policy makers and healthcare
payers make informed decisions on drug listing, coverage
and reimbursement [1]. Value consideration has also been
proposed to be included in clinical guidelines [2]. In many
countries, there is a wealth of information on pharmaceu-
tical price data for use in economic evaluations, for drugs
that have been licensed. Prices are important variables in
their roles as budgeting variables, as well as components of
economic evaluations. However, in some situations, pro-
duct launch is delayed and, prior to a product launch, there
is no publicly available pricing information for the study
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drug. This topic is of particular importance when the policy
maker or manufacturer wants an advance study. In the
absence of market prices, investigators have conducted
economic evaluations, using proxies for the drug prices.
Currently, little is known as to the accuracy of using proxy
drug prices in economic evaluations. Accordingly, we
reviewed the literature on those economic evaluations for
pharmaceuticals that were published prior to product
launch. In our review, we address two questions: (i) what
methods have been used to establish proxy prices for the
yet-to-be-launched pharmaceuticals; and (ii) how do the
prices that result from these proxy pricing strategies com-
pare with actual market prices, after the product launch.
2 Methods
We based our analysis on the US FDA list of newly
licensed drugs from 2010 through 2015 [3]. For each newly
licensed drug, we searched PubMed for any study pub-
lished prior to the licensed year and that had the name of
that drug (trade name or generic name) in the title. We then
limited our sample to those articles that also included the
words ‘cost’ or ‘economic’ in the title. All retained articles
were examined and those that were economic evaluations
were kept for further analysis.
We examined the retained economic evaluations for the
strategies that the authors used to establish price proxies for
the not-yet-licensed drugs, and used the proxy pricing
strategy to estimate US 2016 proxy prices, which were then
compared with the actual US prices.
We used the 2016 Federal Supply Schedule (FSS)
pharmaceutical price list from the US Department of
Veterans Affairs [4] as the primary source of actual and
proxy prices, and obtained both prices for three drugs
(Prolia, Brilinta, and Xarelto) from this list. We used
Canadian prices for the post-launch price of Grazax [5] as
no US prices were available. Similarly, we obtained a post-
launch price of Surfaxin on a drug website as this drug is
not listed in the US product list [6].
3 Results
We identified 17 potential studies in our initial literature
scan and, after examining the abstracts, we eliminated nine
of these studies for the following reasons: a foreign lan-
guage (one study); the study was not an economic evalu-
ation (one study); and the drug was previously licensed,
possibly in a different country where the study was con-
ducted (seven studies). Of the remaining eight studies, we
further excluded two studies: one was a duplicate and one
did not explicitly address non-licensed drug pricing, e.g.
costs for all services, including drugs, were lumped toge-
ther with no explanations. Six studies remained for anal-
ysis, with seven non-licensed drugs.
For the seven drugs, the following methods were used to
determine proxy prices: the drug Grazax was licensed in
another country (UK) and there was a listed UK price [7];
and the drug generic clopidogrel was given an assumed
price [8] based on another study [9]. In one case of
Ruconest [10], the authors stated that they obtained the
proxy price in consultation with the manufacturer, but no
more details were provided. In four cases, the proxy price
was determined using the listed price of a substitute drug
[8, 11–13].
A comparison of drug and proxy prices is shown in
Fig. 1. A substantial difference between actual and proxy
price was noted in five of the seven drugs, but there was no
uniformity in the results. In two of the three cases (Prolia
and Brilinta), where FSS prices were available for the
post-launch study drug and the proxy, the results were
close, but in the third case (Xarelto) the difference was
104.8%. In one extreme case, the standard price could not
be verified.
4 Discussion
Economic evaluations usually appear in print after a drug is
licensed and thus a price is available. However, there have
been instances where analysts have published economic
studies before product launch, and thus drug prices that
were used in the economic evaluation had to be forecast.
We conducted a search of those instances where economic
studies have appeared in print prior to US licensing, and
identified seven cases where drug prices had to be forecast.
We compared the actual 2016 US price (post-launch) with
the 2016 US proxy price using the forecasting technique.
Our results showed a considerable difference between
prices using the forecasting technique and actual prices;
however, no trend was observed.
This is the first study that compared forecast price with
actual (post-launch) price. Information about the reliability
of forecast prices is important if the prospective studies are
to be used in listing decisions. In general, we would rec-
ommend caution in accepting a cost-effectiveness ratio that
is based on forecast prices. If economic evaluations using
forecasted prices are used, then evaluations in which the
study drugs have close substitutes may have better reliabil-
ity. In addition, sensitivity analyses should always be used.
There are several limitations to consider. First, our
analysis was based on a small sample. We did not find
many studies using forecasted prices, therefore, generaliz-
ability is limited. Second, we compared 2016 actual prices
with prices using forecasted methods and 2016 US price.
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There were instances where foreign drug prices entered
into the analysis, and these forecasts might not be as reli-
able. Third, when there are no close substitutes for the
study drug, the forecast may be less reliable. In addition,
cost effectiveness has both costs and effectiveness com-
ponents, and for a complete forecast both must be present.
We have focused on price forecasting only.
5 Conclusions
Forecasting is itself a risky business, and not just in the
case of drug prices, where variances between forecasted
and actual prices can lead to significant errors. It is
important to be aware that these errors may be enhanced,
especially when there are no close substitutes in the mar-
ket. We urge caution in reviewing and accepting a cost-
effectiveness ratio that is based on forecast prices.
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